In the original version of this article (1), the stated disclosure of José Baselga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.
JA, et al
A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors.
©2018 American Association for Cancer Research.
American Association for Cancer Research.